Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name 4r,6r-dorzolamide
Drug ID BADD_D00006
Description Dorzolamide is a non-bacteriostatic sulfonamide derivative [A1304] and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension.[L11377] It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes.[A1303] Unlike oral CA inhibitors, dorzolamide has negligible effects of acid-base or electrolyte disturbances and other systemic adverse effects.[A1304] First marketed in 1995,[A190624] dorzolamide is available in ophthalmic solutions as monotherapy marketed as Trusopt [L11377] or in combination with [timolol] as Cosopt PF.[L11380]
Indications and Usage For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Also used prophylatically for the inhibition of perioperative IOP increase (before neodynium yttrium aluminum garnet laser posterior capsulotomy).
Marketing Status Prescription; Discontinued
ATC Code S01EC03
DrugBank ID DB00869
KEGG ID D07871
MeSH ID C062765
PubChem ID 92087
TTD Drug ID D05UYW
NDC Product Code 14445-404; 70377-081
Synonyms dorzolamide | 4-ethylamino-5,6-dihydro-6-methyl-7,7-dioxide-4H-thieno(2,3-b)thiopyran-2-sulfonamide | 5,6-dihydro-4-ethylamino-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide | dorzolamide, (trans)-isomer | Dorzolamide Chibret | MK 507 | MK-507 | Trusopt | dorzolamide hydrochloride | L 671152 | L-671,152
Chemical Information
Molecular Formula C10H16N2O4S3
CAS Registry Number 120279-89-2
SMILES CCNC1CC(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Choroidal detachment12.01.04.006; 06.09.01.003--Not Available
Colitis ischaemic24.04.08.012; 07.08.01.004--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Conjunctival follicles06.06.02.002--Not Available
Conjunctival oedema06.04.01.001--Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
Corneal erosion06.06.03.003--Not Available
Cough22.02.03.001--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis contact23.03.04.004; 12.03.01.040; 10.01.01.003--Not Available
Dermatitis exfoliative10.01.01.004; 23.03.07.001--
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.002--Not Available
Discomfort08.01.08.003--Not Available
Disorientation17.02.05.015; 19.13.01.002--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Dyspnoea22.02.01.004; 02.01.03.002--
Dysuria20.02.02.002--
Epistaxis24.07.01.005; 22.04.03.001--
Erythema multiforme23.03.01.003; 10.01.03.015--
Erythema of eyelid23.03.06.006; 06.04.04.003--Not Available
Eye discharge06.04.05.001--Not Available
Eye irritation06.04.05.003--Not Available
Eye pain06.08.03.002--
Eyelid oedema23.04.01.003; 10.01.05.001; 06.04.04.004--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages